Stayble Therapeutics

📍 Gothenburg, Sweden🗓 Founded 2015👥 9 employees💰 Last funded Oct 2021
Pharmaceutical Manufacturing🌐 staybletherapeutics.com
Website LinkedIn
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related chronic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and requires minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Early stage· 1
?
Member of the Board
early stage
Sep 2016
Late stage· 1
Gunnar Fernström
Gunnar Fernström
Interim CEO
Board Member
late stage
8 investments
Oct 2021
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Stayble Therapeutics?
Stayble Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Stayble Therapeutics last raise funding?
The most recent investment in Stayble Therapeutics recorded on gritt.io was in October 2021.
When was Stayble Therapeutics founded?
Stayble Therapeutics was founded in 2015.
What industry is Stayble Therapeutics in?
Stayble Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Stayble Therapeutics based?
Stayble Therapeutics is headquartered in Gothenburg, Sweden.